Results 1 to 10 of about 25,184 (248)

H3F3B p.K27I-mutant diffuse midline glioma is a distinct subtype of H3K27-altered diffuse midline glioma [PDF]

Acta Neuropathologica Communications
H3K27-altered diffuse midline glioma (DMG) is a fatal disease, including four subtypes H3.3-mutant, H3.1/H3.2-mutant, H3-wildtype with EZHIP overexpression, and EGFR-mutant.
Lei Cheng, Min Zhou, Tao Luo, Rongfang Dong, Ni Chen, Xinyong Cai, Xingwen Wang, Hao Wu, Zan Chen, Zuowei Wang, Xueling Qi, Dehong Lu, Lianghong Teng, Fengzeng Jian, Leiming Wang   +14 more
doaj   +4 more sources

Case Report: Rare intraventricular H3 K27-altered diffuse midline glioma in an adult [PDF]

Frontiers in Oncology
H3 K27-Altered Diffuse Midline Gliomas are commonly found in children and adolescents in midline locations such as the thalamus, brain stem, and spinal cord.
Merari Jasso, Jay-Jiguang Zhu, Meenakshi B. Bhattacharjee, Georgene W. Hergenroeder   +3 more
doaj   +3 more sources

AI-augmented intraoperative decision-making workflows in diffuse midline glioma biopsy using cryosection pathology [PDF]

Nature Communications
Cryosection pathology is essential for intraoperative diagnosis of diffuse midline gliomas, yet it often leads to diagnostic errors and may prompt unnecessary re-biopsies before completion of the formal molecular assessment.
Yifan Yuan, Qi Yue, Yining Wang, Zunguo Du, Xingfu Wang, Fang Yan, Haixia Cheng, Kaitao Chen, Zanyi Wu, Jianping Song, Chunfeng Song, Lei Bai, Mu Zhou, Mianxin Liu, Ying Mao   +14 more
doaj   +3 more sources

Cholinergic neuronal activity promotes diffuse midline glioma growth through muscarinic signaling. [PDF]

Cell
Neuronal activity promotes the proliferation of healthy oligodendrocyte precursor cells (OPC) and their malignant counterparts, gliomas. Many gliomas arise from and closely resemble oligodendroglial lineage precursors, including diffuse midline glioma ...
Drexler R, Drinnenberg A, Gavish A, Yalçin B, Shamardani K, Rogers AE, Mancusi R, Trivedi V, Taylor KR, Kim YS, Woo PJ, Soni N, Su M, Ravel A, Tatlock E, Midler A, Wu SH, Ramakrishnan C, Chen R, Ayala-Sarmiento AE, Fernandez Pacheco DR, Siverts L, Daigle TL, Tasic B, Zeng H, Breunig JJ, Deisseroth K, Monje M.   +27 more
europepmc   +3 more sources

The proteomic landscape of diffuse midline glioma highlights the therapeutic potential of non-histone protein methyltransferases. [PDF]

Neuro Oncol
Background Diffuse midline glioma (DMG) is a highly aggressive pediatric brain tumor with limited treatment options despite extensive genomic characterization.
Anguraj Vadivel AK, Pajovic S, Siddaway R, Zhu S, Sbergio SG, Matic O, Phillips L, Bu YJ, Nitz M, Hawkins C.   +9 more
europepmc   +2 more sources

Personalized combination therapy for diffuse midline glioma: A case report. [PDF]

Oncol Lett
The present study aimed to analyze the efficacy of personalized combination therapy for patients with H3K27M mutant diffuse midline glioma (DMG) so as to explore new treatment options for further clinical research.
Sun M, Zheng J, Gong L, Li Z, Wang L.
europepmc   +2 more sources

Germline analysis of an international cohort of pediatric diffuse midline glioma patients. [PDF]

Neuro Oncol
Background Factors that drive the development of diffuse midline gliomas (DMG) are unknown. Our study aimed to determine the prevalence of pathogenic/likely pathogenic (P/LP) germline variants in pediatric patients with DMG.
Mateos MK, Ajuyah P, Fuentes-Bolanos N, El-Kamand S, Barahona P, Altekoester AK, Mayoh C, Holliday H, Liu J, Cui L, Pfaff E, Mackay A, Resnick AC, Pinese M, Lau LMS, Khuong-Quang DA, Dias K, Goudie C, Salkeld A, Rokita JL, Jones DTW, Juretic N, Hayden E, Pfister SM, Kramm CM, Blattner-Johnson M, Jabado N, Tsoli M, Vittorio O, Mueller S, Guo Y, Tucker K, Waszak SM, Perreault S, Jones C, Wong-Erasmus M, Cowley MJ, Ziegler DS.   +37 more
europepmc   +2 more sources

An Unusual Case of H3K27-Altered Diffuse Midline Glioma Presenting as a Third Ventricular Mass. [PDF]

Cureus
Diffuse midline gliomas (DMGs) are rare central nervous system tumors, typically arising from astrocytes. The H3K27-altered DMG subtype is defined by a specific histone protein mutation that disrupts normal cellular regulation and promotes unchecked ...
Mitchel H, Huff T, Pickard K, Carmody R, Ozgur H, Elliott A, Rogers S.   +6 more
europepmc   +2 more sources

Transient mRNA CAR T cells targeting GD2 provide dose-adjusted efficacy against diffuse midline glioma and high-grade glioma models. [PDF]

Neuro Oncol
Background Diffuse midline glioma (DMG) and high-grade glioma are devastating pediatric central nervous system tumors that remain incurable. Recent chimeric antigen receptor (CAR) T cell studies have shown proof of concept and early signs of efficacy ...
Foster JB, Madsen PJ, Harvey K, Griffin C, Stern A, Patterson L, Joshi N, Dickson C, McManus O, Beaubien E, Wilson C, Beale DR, Baubet V, Goel PN, Vitanza NA, Nazarian J, Koptyra M, Storm PB, Resnick AC.   +18 more
europepmc   +2 more sources

Small Extracellular Vesicles From Radioresistant H3K27M-Pediatric Diffuse Midline Glioma Cells Modulate Tumor Phenotypes and Radiation Response. [PDF]

J Extracell Vesicles
Pediatric diffuse midline gliomas with the Histone 3 lysine 27-to-methionine mutation (H3K27M-pDMG) are aggressive brain tumors characterized by intrinsic resistance to radiation therapy, the current standard of care.
Oza VD, Flores KA, Chernyavskaya Y, Al-Hamaly MA, Smith CB, Bruntz RC, Blackburn JS.   +6 more
europepmc   +2 more sources